Nothing Special   »   [go: up one dir, main page]

DK0393438T3 - TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor - Google Patents

TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor

Info

Publication number
DK0393438T3
DK0393438T3 DK90106624T DK90106624T DK0393438T3 DK 0393438 T3 DK0393438 T3 DK 0393438T3 DK 90106624 T DK90106624 T DK 90106624T DK 90106624 T DK90106624 T DK 90106624T DK 0393438 T3 DK0393438 T3 DK 0393438T3
Authority
DK
Denmark
Prior art keywords
tnf
tnf receptor
receptor
binding protein
binding proteins
Prior art date
Application number
DK90106624T
Other languages
English (en)
Inventor
Rudolf Dr Hauptmann
Ingrid Dr Maurer-Fogy
Christian Dr Stratowa
Adolf Dr Himmler
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE3913101A external-priority patent/DE3913101A1/de
Priority claimed from DE19893920282 external-priority patent/DE3920282A1/de
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0393438T3 publication Critical patent/DK0393438T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK90106624T 1989-04-21 1990-04-06 TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor DK0393438T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3913101A DE3913101A1 (de) 1989-04-21 1989-04-21 Tnf-(alpha) bindende proteine und dafuer kodierende dnas
DE19893920282 DE3920282A1 (de) 1989-06-21 1989-06-21 Tnf-rezeptor, tnf bindende proteine und dafuer kodierende dnas

Publications (1)

Publication Number Publication Date
DK0393438T3 true DK0393438T3 (da) 2005-05-30

Family

ID=25880137

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90106624T DK0393438T3 (da) 1989-04-21 1990-04-06 TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor

Country Status (7)

Country Link
US (5) US6294352B1 (da)
EP (1) EP0393438B1 (da)
AT (1) ATE289350T1 (da)
DE (1) DE59010941D1 (da)
DK (1) DK0393438T3 (da)
ES (1) ES2238070T3 (da)
HK (1) HK1017820A1 (da)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US5811261A (en) * 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
DK0393438T3 (da) * 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
DE10399036I1 (de) * 1989-08-07 2004-04-01 Peptide Technology Ltd Bindeligande für Tumornekrosisfaktor.
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
DE10399023I2 (de) * 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
GB2246569A (en) * 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
AU1235692A (en) * 1991-01-18 1992-08-27 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
CA2107340C (en) * 1991-06-19 2003-06-10 Gunther Adolf Monoclonal antibodies against human tnf-binding protein i (tnf-bp i)
WO1993004375A1 (en) * 1991-08-23 1993-03-04 Nchip, Inc. Burn-in technologies for unpackaged integrated circuits
US5770401A (en) * 1991-10-15 1998-06-23 Mullarkey; Michael F. Methods and compositions for treating allergic reactions
IL101769A (en) 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
US6579697B1 (en) 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
US5847099A (en) * 1994-10-19 1998-12-08 Genetics Institute, Inc. TNF receptor death domain ligand proteins
US5712381A (en) 1994-10-19 1998-01-27 Genetics Institute, Inc. MADD, a TNF receptor death domain ligand protein
EP2017337A1 (en) * 1995-04-27 2009-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
CA2244664C (en) 1996-02-09 2008-06-03 Amgen Inc. Composition comprising interleukin-1 inhibitor and controlled release polymer
KR970065714A (ko) * 1996-03-11 1997-10-13 성재갑 종양 괴사 인자 수용체의 세포질내 도메인 단백질 및 이의 변형체
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
EP0960196A4 (en) * 1996-10-04 2002-10-29 Immunex Corp CELL DEATH CAUSING RECEPTOR
JP2001502912A (ja) * 1996-10-30 2001-03-06 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒト腫瘍壊死因子レセプター―ライク２
WO1998024477A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6893838B1 (en) 1998-04-07 2005-05-17 Genetics Institute Llc DADD, death activator death domain protein
DE19948867A1 (de) * 1998-10-09 2000-08-17 Bioserv Ag TNFalpha bindende Peptide und ihre Anwendung für Detektion, Inaktivierung und/oder Entfernung von TNFalpha aus biologischen Flüssigkeiten
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU4541101A (en) 2000-03-02 2001-09-12 Xencor Inc Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
BR0001078A (pt) * 2000-04-06 2003-05-13 Maria Amalia Rotolo De Moraes Método e aparelho de estìmulo positivo mental
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
ATE431405T1 (de) 2000-09-05 2009-05-15 Amgen Inc Tnf-rezeptor-ähnliche moleküle und deren anwendungen
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
DE10059616A1 (de) * 2000-12-01 2002-06-06 Zimmer Ag Verfahren zum Erzeugen von Polycarbonaten
DE60235989D1 (de) 2001-06-26 2010-05-27 Amgen Fremont Inc Antikörper gegen opgl
US6886964B2 (en) * 2001-06-26 2005-05-03 Allan Gardiner Illuminator with filter array and bandwidth controller
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1448772B1 (en) * 2001-11-30 2007-07-18 Applied Research Systems ARS Holding N.V. Methods of increasing expression levels of human tnf receptor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
BR0315807A (pt) * 2002-11-15 2005-09-20 Ares Trading Sa Processo para purificação das proteìnas ligadas a tnf usando imac
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7344886B2 (en) 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
EP1578799B8 (en) 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
EP1578782A4 (en) * 2002-12-30 2007-09-12 Amgen Inc COSTIMULATING FACTORIAL THERAPY
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
EP1781699A1 (en) * 2004-08-16 2007-05-09 Novo Nordisk A/S Multimers of peptides
MX2007006602A (es) * 2004-12-02 2007-12-10 Domantis Ltd Peptidos de dominio plad con vida media en suero aumentada debido a conjugacion con anticuerpos de dominio.
US7785834B2 (en) * 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
AU2006315758A1 (en) * 2005-11-10 2007-05-24 Ercole Biotech, Inc. Splice switching oligomers for TNF superfamily receptors and their use in treatment of disease
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US20090264353A1 (en) * 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
EP1953222A1 (en) 2007-01-24 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of cell growth
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
TW201009075A (en) 2008-07-23 2010-03-01 Boehringer Ingelheim Pharma Improved production host cell lines
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US20110086770A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Combinatorial Libraries Based on C-type Lectin-like Domain
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
PT3295957T (pt) 2010-01-15 2019-11-12 Kirin Amgen Inc Formulação de anticorpo anti il-17ra e regimes terapêuticos para o tratamento de psoríase
ES2626418T3 (es) 2010-12-23 2017-07-25 Hanall Biopharma Co., Ltd. Polipéptido modificado del receptor-1 del factor de necrosis tumoral humano o fragmento del mismo y procedimiento de preparación del mismo
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2014102103A2 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Heterologous intron within a signal peptide
WO2014102101A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
EP3126392B1 (en) 2014-03-31 2019-09-11 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
MA47362A (fr) 2017-01-30 2019-12-04 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
AU2017398101A1 (en) 2017-02-07 2019-08-01 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN150740B (da) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4560649A (en) * 1981-10-15 1985-12-24 Cornell Research Foundation Assaying for hLH or hCG with immobilized hormone receptors
JPH0751511B2 (ja) * 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4966888A (en) * 1985-07-08 1990-10-30 Cornell Research Foundation, Inc. hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4578335A (en) * 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
CA1339269C (en) * 1984-05-21 1997-08-12 Douglas P. Cerretti Purification of and cloning of the gene for interleukin-2 receptor
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
CA1283046C (en) * 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
US4693684A (en) * 1986-05-30 1987-09-15 Johnson & Johnson Dental Products Company Ratchet type dispenser for dental materials
US4931544A (en) * 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5359037A (en) * 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
US5811261A (en) * 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
IL92697A (en) * 1989-12-13 1996-03-31 Yeda Res & Dev Molecular cloning of TNF binding protein
IL94039A (en) * 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DK0393438T3 (da) * 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
DE3920282A1 (de) * 1989-06-21 1991-01-03 Boehringer Ingelheim Int Tnf-rezeptor, tnf bindende proteine und dafuer kodierende dnas
DE3913101A1 (de) * 1989-04-21 1990-10-31 Boehringer Ingelheim Int Tnf-(alpha) bindende proteine und dafuer kodierende dnas
DE3922089A1 (de) * 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
EP0398327B2 (en) * 1989-05-18 2013-02-20 Yeda Research And Development Co., Ltd. Tumor necrosis factor binding protein II, its purification and antibodies thereto
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
GB8919598D0 (en) * 1989-08-30 1989-10-11 Exxon Chemical Patents Inc Coating compositions
AU630497B2 (en) * 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
DE10399023I2 (de) * 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
JPH0578396A (ja) * 1989-12-13 1993-03-30 Yeda Res & Dev Co Ltd ヒト腫瘍壊死因子結合蛋白
US5136021A (en) * 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
FI87492C (fi) 1990-06-12 1993-01-11 Valmet Paper Machinery Inc Foerfarande och anordning foer maetning och reglering av bestrykningsmaengden
GB2246569A (en) * 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
WO1992001002A1 (fr) * 1990-07-11 1992-01-23 Teijin Limited Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation
EP0540612A1 (en) * 1990-07-20 1993-05-12 Pharmacia AB Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU1235692A (en) * 1991-01-18 1992-08-27 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases
DE69233068T2 (de) * 1991-02-27 2004-01-22 Micromet Ag Serin-reiche peptidlinker
GEP20033082B (en) * 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
JPH07504203A (ja) * 1992-09-15 1995-05-11 イミュネックス・コーポレーション 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法
US5359307A (en) * 1993-08-12 1994-10-25 Hewlett-Packard Corporation High voltage relay

Also Published As

Publication number Publication date
EP0393438A2 (de) 1990-10-24
US6440693B1 (en) 2002-08-27
HK1017820A1 (en) 1999-11-26
US6294352B1 (en) 2001-09-25
US20020169118A1 (en) 2002-11-14
DE59010941D1 (de) 2005-03-24
US6417158B1 (en) 2002-07-09
ES2238070T3 (es) 2005-08-16
EP0393438A3 (de) 1991-06-19
EP0393438B1 (de) 2005-02-16
ATE289350T1 (de) 2005-03-15
US6271346B1 (en) 2001-08-07

Similar Documents

Publication Publication Date Title
DK0393438T3 (da) TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
DE3587939D1 (de) Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, dafür kodierende DNS und diese DNS verwendendes Testverfahren.
ATE114724T1 (de) Antikörper gegen tnf-bindungsprotein i und deren f(ab)-fragmente.
ATE451390T1 (de) Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys)
DE69232309D1 (de) Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen
ATE80180T1 (de) Herstellung eines igg-bindenden proteins zum erleichtern der weiterverarbeitung mittels ''protein-engineering''.
DE69321555D1 (de) ECK-Rezeptor-Liganden
AU6250098A (en) Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
BR9708518A (pt) Moduladores de fator associado a receptor tnf (traf) sua preparação e uso
IS3197A7 (is) Magnbundin ákvörðun kjarnasýrusameinda og samstæðefni notuð við hana
PT84089B (pt) Sequencias de adn codificando para proteinas possuindo a actividade biologica dos inibidores de husi-tipo i, processos biotecnologicos para a preparacao das referidas proteinas e de composicoes farmaceuticas contendo as referidas proteinas
DK71986A (da) Polypeptider fra rhinovirusstamme hrv2 samt de herfor kodende dna-molekyler, fremgangsmaade til polypeptidernes fremstilling og deres anvendelse
BR9712793A (pt) Fatores homólogos (fhfs) ao fator do desenvolvimento de fibroblasto e métodos de uso
SE8901342L (sv) Biologiska material, foerfaranden foer framstaellning av biologiska material samt foer anvaendning av saadana material i terapi
SG128403A1 (en) Tnf-receptors, tnf binding proteins and dnas coding for them
ATE187202T1 (de) Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung
ATE162224T1 (de) Crf bindungsproteine
ATE111920T1 (de) Lymphokine, dns-sequenzen, die diese lymphokine kodieren, und sie enthaltende pharmazeutische zusammensetzungen.
Wakui et al. High-yield purification of the complex-forming glycoprotein in urine from normal and abnormal subjects.
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
Tyrsin et al. Homology of histones H2B from calf thymus and P4B from slime mold Physarum polycephalum